
Novo Nordisk and Lumen Bioscience have entered into a research collaboration, according to a press release from the US company.
According to their agreement, the companies will evaluate Lumen's technology platform and explore new strategies for creating oral biologics for treating obesity and other cardiometabolic diseases.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app